Clinical Trial Search

Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants

Primary: Sensitivity — 59 percentage of participants

Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78

Primary: Prevalence of Pancreatic Cysts During Routine EUS — 46 participants found to have a cyst

Primary: S-MRCP and S-EUS Concordance

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL

Primary: Number of Patients Where TraceIT Tissue Marker Placement Achieved — 6 Participants

Primary: Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume — 78; 74; 73 percentage of cyst volume aspirated — p=0.84

Primary: Decreased Secretions — 1 participants

Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…

Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants

Primary: Tumor Response — 5; 3 Participants

Primary: Diagnostic Yield of Capillary Technique — 75.4 percentage of specimen

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804

Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants

Primary: The T2* Values in the Diagnosis of AP — 25.86; 21.06 ms — p=<0.01

Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants

Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants

Primary: Successful Procedure Completion — 70; 5 participants

Primary: Pain Reduction — 12 Participants — p=0.999

Primary: Local Control Rate — 1 Participants

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Combined Clinically Significant Postoperative Pancreatic Fistula and Intra-abdominal Abscess — 8 Participants

Primary: Late Gastrointestinal Toxicities — 13 Participants

Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants

Primary: Survival — 37; 31 participants